Abstract
HIV protease inhibitors have been shown to exert antiangiogenic and antitumor actions independently from their antiretroviral effect. Based on these studies, HIV-seronegative patients with classic Kaposi's sarcoma were treated with indinavir and followed for clinical evolution, drug pharmacokinetics and Kaposi's sarcoma biomarkers. A favorable clinical course was associated with high drug plasma levels, reduced production of basic fibroblast growth factor, lower numbers of circulating endothelial cells, and a decrease in antibody titers against human herpesvirus 8.
Original language | English |
---|---|
Pages (from-to) | 534-538 |
Number of pages | 5 |
Journal | AIDS (London, England) |
Volume | 23 |
Issue number | 4 |
DOIs | |
Publication status | Published - Feb 20 2009 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Infectious Diseases